A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

The recruitment status of this study is unknown because the information has not been verified recently.

Verified July 2004 by Trimeris.
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

Trimeris

ClinicalTrials.gov Identifier:

NCT00048217

First received: October 28, 2002

Last updated: June 23, 2005

Last verified: July 2004

History of Changes

Purpose

Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Condition	Intervention	Phase
HIV Infections	Drug: T-1249	Phase 1 Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Masking: Open Label Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by Trimeris:

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Completion T1249-102;
Currently failing a T-20 containing regimen

Exclusion Criteria:

Non-completion of T1249-102.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048217

Locations


United States, North Carolina
Trimeris
Durham, North Carolina, United States, 27707

Sponsors and Collaborators

Trimeris

More Information


ClinicalTrials.gov Identifier:	NCT00048217 History of Changes
Other Study ID Numbers:	T1249-105
Study First Received:	October 28, 2002
Last Updated:	June 23, 2005
Health Authority:	United States: Food and Drug Administration

Keywords provided by Trimeris:


Treatment Experienced

Additional relevant MeSH terms:


HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases	Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases

ClinicalTrials.gov processed this record on September 23, 2016

To Top